Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 5,457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Tumor Malignancies, Cancer Clear all
Completed Phase 1 Interventional

Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma

NCT00124605
View directory record Official record
Conditions
Refractory Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pamidronate disodium, arsenic trioxide, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 27, 2026, 5:33 PM EDT
Not yet recruiting Not applicable Interventional

A Spiritual Health Intervention (PATH) for Improving Spiritual, Religious and Emotional Distress in Cancer Patients

NCT07545291
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Spiritual Therapy, Survey Administration, Interview
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 27, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

NCT02628574
View directory record Official record
Conditions
Solid Tumors
Interventions
TRX518 monotherapy, TRX518 with gemcitabine, TRX518 with pembrolizumab, TRX518 with nivolumab
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Chicago, Illinois • Albuquerque, New Mexico • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 27, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

NCT00859118
View directory record Official record
Conditions
Neoplasms
Interventions
AG-013736
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting No phase listed Observational

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

NCT06640010
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 27, 2026, 5:33 PM EDT
Not listed Phase 1 Interventional

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

NCT05525559
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ET0038
Drug
Lead sponsor
Etern BioPharma (Shanghai) Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485
View directory record Official record
Conditions
Low-grade Glioma, Advanced Solid Tumor
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
6 Months to 25 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 27, 2026, 5:33 PM EDT
Completed Phase 1 Interventional Results available

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

NCT01447225
View directory record Official record
Conditions
Solid Tumors
Interventions
MM-121, Carboplatin, Pemetrexed, Cabazitaxel, Gemcitabine
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Lafayette, Indiana • Buffalo, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385925
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
TSN1611
Drug
Lead sponsor
Tyligand Pharmaceuticals (Suzhou) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

NCT07387068
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
GEN1079
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 5:33 PM EDT
Terminated No phase listed Observational

Ultrasound and Other Images of Artery Blockages

NCT01419574
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 27, 2026, 5:33 PM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 27, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

NCT00420524
View directory record Official record
Conditions
Advanced Malignancies, Tumors
Interventions
Patupilone/EPO906
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
La Jolla, California • Albuquerque, New Mexico • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

NCT06069570
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases From Solid Tumors
Interventions
KB-GDT-01
Biological
Lead sponsor
Kiromic BioPharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tucson, Arizona • Beverly Hills, California • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 27, 2026, 5:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

NCT02261805
View directory record Official record
Conditions
Cancer, Small Cell Lung Cancer
Interventions
Ganetespib, Doxorubicin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

NCT04299191
View directory record Official record
Conditions
High-grade Glioma, Solid Tumor, Unspecified, Child
Interventions
LAM561
Drug
Lead sponsor
Laminar Pharmaceuticals
Industry
Eligibility
Up to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Little Rock, Arkansas • Miami, Florida • Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 27, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

3-AP in Treating Patients With Advanced Cancer

NCT00006218
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting Not applicable Interventional

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

NCT06896162
View directory record Official record
Conditions
Solid Tumor Malignancies, Metastatic Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Bladder Cancer
Interventions
Expert Review, Blood or tissue samples collection., The Precision Oncology Navigation
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

NCT00324480
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, vorinostat, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional

GTB-5550 in Advanced Solid Tumors

NCT07541573
View directory record Official record
Conditions
Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
Interventions
GTB-5550
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 27, 2026, 5:33 PM EDT
Completed Phase 2 Interventional

Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin

NCT00004005
View directory record Official record
Conditions
Carcinoma of Unknown Primary, Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
fluorouracil, irinotecan hydrochloride, leucovorin calcium, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 27, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

NCT03815682
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
Arm A: RPTR-147:1, Arm B: RPTR-147:1 and Pembrolizumab, Arm C: RPTR-147:2
Biological
Lead sponsor
Repertoire Immune Medicines
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 27, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 27, 2026, 5:33 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

NCT02536183
View directory record Official record
Conditions
Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Soft Tissue Sarcomas, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumors
Interventions
Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin
Device · Drug
Lead sponsor
AeRang Kim
Other
Eligibility
Up to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 27, 2026, 5:33 PM EDT